# US 2009/0269399 A1 · Phosphate-binding magnesium salts and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269399 A1
- Document ID: US20090269399A1
- Status: Published application
- Kind: A1
- Application number: 12/422,012
- Filed: 2009-04-10
- Published: 2009-10-29
- Earliest claimed: 2009-04-10
- Assignees: Cypress Pharmaceutical, Inc.
- Inventors: Robert L. Lewis; Charles E. Day
- Web page: https://patentgrep.com/patent/US20090269399A1

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 33/08: Oxides; Hydroxides
- A61K 33/10: Carbonates; Bicarbonates
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 39/04: Chelating agents
- A61K 9/2806: {Coating materials}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

## Claims

### Claim 1

A composition suitable for treating hyperphosphatemia comprising a therapeutically effective dose of at least one calcium salt and at least one phosphate-binding magnesium salt.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the at least one phosphate-binding magnesium salt binds at least about 50 mg phosphate per gram magnesium salt.

### Claim at position 3

3-6. (canceled)

### Claim 7 (depends on 1)

The composition of claim 1, wherein the at least one calcium salt is selected from the group consisting of calcium acetate, calcium aceturate, calcium adipate, calcium alaninate, calcium alginate, calcium aminobutyrate, calcium arginate, calcium ascorbate, calcium aspartate, calcium benzoate, calcium besylate, calcium betainate, calcium bromide, calcium buteprate, calcium butyrate, calcium caproate, calcium carbesilate, calcium carbonate, calcium carboxymethylcellulose, calcium carnitinate, calcium chloride, calcium ciclotate, calcium citrate, calcium cypionate, calcium enanthate, calcium esylate, calcium ethandisulfonate, calcium formate, calcium fumarate, calcium glucarate, calcium gluceptate, calcium gluconate, calcium glucuronate, calcium glutamate, calcium glycinate, calcium hippurate, calcium hyclate, calcium hydroxide, calcium iodide, calcium isethionate, calcium lactate, calcium lactobionate, calcium levulinate, calcium lysinate, calcium malate, calcium maleate, calcium mesylate, calcium metilsulfate, calcium methylsulfate, calcium naphthoate, calcium napsylate, calcium nicotinate, calcium nitrate, calcium oleate, calcium orotate, calcium oxide, calcium oxoglurate, calcium pamoate, calcium pantothenate, calcium picolinate, calcium pivalate, calcium polygalacturonate, calcium propionate, calcium sorbate, calcium steaglate, calcium stearate, calcium stearyl-2-lactylate, calcium succinate, calcium sulfate, calcium sulfite, calcium tartrate, calcium tebutate, calcium tosylate, calcium triflutate, calcium xinafoate, and combination thereof.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the at least one phosphate-binding magnesium salt is selected from the group consisting of magnesium aminobutyrate, magnesium arginate, magnesium aspartate, magnesium betainate, magnesium carnitinate, magnesium glycinate, magnesium hydroxide, magnesium lysinate, magnesium oxide, magnesium propionate, and combination thereof.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the mass ratio of the at least one calcium salt to the at least one phosphate-binding magnesium salt is between about 100:1 and about 1:100.

### Claim at position 7

10-16. (canceled)

### Claim 17 (depends on 1)

The composition of claim 1, wherein the at least one calcium salt comprises calcium acetate, and the at least one phosphate-binding magnesium salt comprises magnesium glycinate.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The composition of claim 1, wherein the composition is formulated for oral administration.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the composition is in a form of a tablet, a cachet, a hard gelatin capsule, a soft gelatin capsule, a lozenge, suspension, or a bead.

### Claim 21 (depends on 20)

The composition of claim 20 further comprising an enteric coating.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the enteric coating comprises acetyltributyl citrate, carbomers, cellulose acetate phthalate, cellulose acetate succinate, ethyl cellulose, guar gum, hypromellose acetate succinate, hypromellose phthalate, polymethacrylates, polyvinyl acetate phthalate, shellac, tributyl citrate, triethyl citrate, white wax and/or zein.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 19)

The composition of claim 19, wherein the composition is formulated as a nutritional supplement.

### Claim 26

A composition suitable for treating hyperphosphatemia comprising a therapeutically effective dose of at least one phosphate-binding magnesium salt, wherein the at least one phosphate-binding magnesium salt binds at least about 50 mg phosphate per gram.

### Claim 27

(canceled)

### Claim 28

A composition suitable for treating hyperphosphatemia comprising a therapeutically effective dose of at least one phosphate-binding magnesium salt, wherein the at least one phosphate-binding magnesium salt is not magnesium carbonate.

### Claim at position 20

29-40. (canceled)

### Claim 41

A composition suitable for treating hyperphosphatemia consisting essentially of a calcium salt and a phosphate-binding magnesium salt.

### Claim at position 22

42-63. (canceled)

### Claim 64 (depends on 1)

A method of treating hyperphosphatemia comprising administering to a subject in need of treatment the composition of claim 1.

### Claim 65

A method of treating hyperphosphatemia comprising administering to a subject in need of treatment a calcium salt and a phosphate-binding magnesium salt.

### Claim 66 (depends on 65)

The method of claim 65, wherein the phosphate-binding magnesium salt binds at least about 50 mg phosphate per gram.

### Claim 67 (depends on 65)

The method of claim 65, wherein the phosphate-binding magnesium salt is not magnesium carbonate.

### Claim at position 27

68-91. (canceled)

### Claim 92

A method of treating hyperphosphatemia comprising administering to a subject in need of treatment a phosphate-binding magnesium salt, wherein the phosphate-binding magnesium salt binds at least about 50 mg phosphate per gram.

### Claim 93

A method of treating hyperphosphatemia comprising administering to a subject in need of treatment a phosphate-binding magnesium salt, wherein the phosphate-binding magnesium salt is not magnesium carbonate.

### Claim at position 30

94-106. (canceled)
